BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2015
At a glance
- Drugs Ridaforolimus (Primary) ; Cetuximab
- Indications Colon cancer; Head and neck cancer; Non-small cell lung cancer
- Focus Adverse reactions
- 22 Feb 2013 Planned end date changed from 1 Dec 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 22 Feb 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 May 2012 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.